Meril Launches Myval Octapro THV At Global Cardiology Event

Meril Life Sciences, a global med-tech leader specialising in cardiovascular and structural heart solutions, has launched its latest innovation, the Myval Octapro Transcatheter Heart Valve (THV), at the GISE 2024 and PCR London Valves 2024 conferences. This device is poised to transform structural heart care with its advanced features designed for precision and enhanced clinical outcomes.

The Myval Octapro THV introduces low-frame foreshortening technology, allowing operators to achieve precise deployment and better commissural alignment during procedures. It also offers an extensive size matrix, including intermediate and extra-large valve sizes, to ensure personalised solutions tailored to diverse patient anatomies.

At PCR London Valves 2024, Meril presented new data from the subset analysis of the LANDMARK trial, which complements earlier findings published in The Lancet. The results, now featured in EuroIntervention, demonstrated the Myval THV series' safety and efficacy compared to the Sapien and Evolut THV series. Myval exhibited a lower permanent pacemaker implantation rate, at 15.0 per cent compared to 17.3 per cent for Sapien, while showing superior hemodynamic performance and reduced moderate or severe valve regurgitation.

Dr. Ashok Seth, Chairman of Fortis Escorts Heart Institute, expressed his support for this innovation, stating, “The Myval Octapro THV represents a next-generation solution with minimal foreshortening and a broad size range, including intermediate options that fit diverse anatomies. Approximately 50 per cent of Myval THV implants involve intermediate sizing, making it an excellent choice for varied annular anatomies.”

Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, highlighted the global recognition of the Myval Octapro. He said, “The positive reception of our latest THV underscores Meril’s dedication to advancing TAVR technology and improving patient outcomes through innovation. We are committed to collaborating with clinicians worldwide to deliver life-changing solutions for severe aortic stenosis.”

The LANDMARK trial findings underscored comparable safety and effectiveness outcomes between Myval and Sapien at 24.7 per cent and 24.1 per cent, respectively, while Myval matched Evolut in composite endpoints, achieving 24.7 per cent versus Evolut’s 30 per cent. In the small aortic annulus cohort, Myval demonstrated superior hemodynamics compared to Sapien and fewer clinical events than Evolut, despite Evolut’s better hemodynamic performance.